| Document |
Document Title |
|
WO/2021/094312A1 |
The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...
|
|
WO/2021/088787A1 |
Disclosed is a quinazoline compound used as an AXL inhibitor. The structure of the quinazoline compound is as shown in general formula (I), and the definition of each substituent is as described in the description. Further provided is a ...
|
|
WO/2021/088957A1 |
Disclosed are a novel aromatic heterocyclic compound as an ATX (Autotaxin) inhibitor, a pharmaceutical composition containing the compound, and a use of the compound and the composition in treatment of a disease having a pathological cha...
|
|
WO/2021/088945A1 |
The present invention falls within the field of medical chemistry and relates to a class of compounds as SHP2 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (I), or an isome...
|
|
WO/2021/089032A1 |
Disclosed are a compound as represented by general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereoisomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt...
|
|
WO/2021/082901A1 |
Provided are a phenylisoxazoline compound and use thereof. The phenylisoxazoline compound is represented by general formula (I). The compound of general formula (I) has good herbicidal activity, and can effectively control barnyard grass...
|
|
WO/2021/078120A1 |
Provided herein are a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical composi...
|
|
WO/2021/078141A1 |
The present invention discloses a novel purine derivative represented by formula (I) or a pharmaceutically acceptable salt thereof, intermediate and application thereof in preparation of a medicament for treating or preventing a cancer. ...
|
|
WO/2021/073456A1 |
Provided are a class of macrocyclic and cage-like molecules based on a biphenylarene and derivative compounds, a synthesis method therefor and the use thereof. A series of new macrocycles and molecular cages are obtained in a high yield ...
|
|
WO/2021/063404A1 |
A biaryl compound. Specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/066873A1 |
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a ...
|
|
WO/2021/062549A1 |
The present disclosure relates to redox active materials, such as the compound of formula (I), comprising at least one 2,5-dithio-7- azabicyclo(2.2. l)heptane unit connected to a surface thereof, as well as processes for making said redo...
|
|
WO/2021/067521A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
|
WO/2021/067827A1 |
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
|
|
WO/2021/062318A1 |
Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical composition...
|
|
WO/2021/048342A1 |
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2021/050994A1 |
Provided herein are heterobicyclic cyclopropanecarboxamide and heterobicyclic carboxamide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or...
|
|
WO/2021/042178A1 |
This invention relates to methods of treating, preventing, managing and/or controlling opioid withdrawal and/or a symptom associated with the opioid withdrawal. Compounds, compositions, medicaments and kits are provided that may be used ...
|
|
WO/2021/043703A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/045469A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/043973A1 |
A compound of compound according to formula (I), wherein X is selected from the group consisting of CH, CCl and N, Z is selected from the group consisting of CH2COOH, CH(CH3)COOH, C(CH3)2COOH and CH2F, D is a single bond connecting A and...
|
|
WO/2021/040310A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting element using same.
|
|
WO/2021/038452A1 |
The present invention relates to compounds having a tetracyclic system and the use thereof as new therapeutic agents in the treatment of acute myeloid leukemia (AML), preferably in FLT3/ITD hemizygote patients resistant to conventional t...
|
|
WO/2021/032588A1 |
The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds ...
|
|
WO/2021/028645A1 |
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein ac...
|
|
WO/2021/030686A1 |
The present invention includes crystalline forms of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-
benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I). Furthermore, the present invention prov...
|
|
WO/2021/030554A1 |
The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
|
|
WO/2021/030556A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and phar...
|
|
WO/2021/030671A1 |
The present invention includes 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-
benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) or a pharmaceutically acceptable salt thereof for use in trea...
|
|
WO/2021/028649A1 |
The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein ac...
|
|
WO/2021/030278A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2021/030552A1 |
Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same,...
|
|
WO/2021/026109A1 |
Disclosed are bispecific compounds (degraders) that target CDK7 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.
|
|
WO/2021/026009A1 |
The present disclosure relates to compounds of formula (IA') as STING (Stimulator of Interferon Genes) agonists for use in the treatment of e.g. cancer, obesity, liver injuries, sugar-lipid metabolism and virus infections. The present de...
|
|
WO/2021/021634A1 |
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been di...
|
|
WO/2021/021986A1 |
The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.
|
|
WO/2021/018194A1 |
Provided are compounds represented by Formula I, wherein R1, R 2a, R 2b, R 2c, R 2d, R 3, R 4a, R 4b, A, L, X, Y, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Fo...
|
|
WO/2021/016289A1 |
Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R1, R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as modulat...
|
|
WO/2021/005043A1 |
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseas...
|
|
WO/2021/005034A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein R1, R2, X, and Y are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the comp...
|
|
WO/2021/005436A1 |
The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liv...
|
|
WO/2021/001453A1 |
The present invention is directed to compounds according to Formula (I) and the pharmaceutically acceptable salts thereof. The compounds can be used as modulators of Estrogen-related Receptor alpha (ERRĪ±) and have utility in the treatme...
|
|
WO/2021/001567A1 |
The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder in a mammalian subject, wherein the T cell has been engineered (i) to overexpress BLIMP1 and/or (ii) to knock-out or decreas...
|
|
WO/2021/000046A1 |
Described herein is a synergistic combination comprising a quorum-sensing inhibitor and/or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and meth...
|
|
WO/2020/254697A1 |
The present invention relates to novel compounds (I) that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities responsive to modulation or inhibition of the activation of a compo...
|
|
WO/2020/253659A1 |
Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2020/247054A1 |
The present disclosure provides, e.g., compounds, compositions, kits, methods of synthesis, and methods of use, involving epipolythiodiketopiperazines and polythiodiketopiperazines.
|
|
WO/2020/247160A1 |
The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I), tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautom...
|
|
WO/2020/247336A1 |
Disclosed herein are Pifithrin compounds, methods of treating Rett Syndrome, brain fusion organoids comprising a fusion between a cerebral cortex (Cx) organoid and the ganglionic eminence (GE) organoid, one of which comprises, consists e...
|
|
WO/2020/243519A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
